OncoHost presents new data on early detection of immunotherapy resistance
OncoHost will present research at ISLB 2026 detailing how plasma proteomics can predict immunotherapy response in advanced lung cancer patients before radiologic signs appear.
At the ISLB 2026 conference, OncoHost is reporting on findings that suggest longitudinal plasma proteomics can identify disease progression in advanced non-small cell lung cancer (NSCLC) earlier than current radiologic imaging standards. The study focuses on monitoring protein profiles to predict patient survival and overall response to immunotherapy treatments.
For patients with advanced cancer, the delay between ineffective treatment and clinical identification of that failure remains a significant hurdle. This study suggests that proteomic analysis could offer a more rapid window into whether a patient is developing resistance to therapy, potentially allowing for more timely intervention or shifts in care strategy.
The findings highlight the shift toward precision diagnostics in oncology. By utilizing plasma samples, the approach aims to provide a less invasive and more predictive tool compared to standard assessments, marking a potential step forward in personalized cancer management.